Cullinan Therapeutics, Inc

CGEMNASDAQ · Biological Products, (No Diagnostic Substances)

Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

64.3M

on 2026-06-30, from 43.1M on 2024-03-31 10-Q ↗

Newest

No limit

S-3ASR of 2026-04-28. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$200.0M

TD Securities (USA), agreement of 2026-04-28. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

8.4 quarters

$334.5M on 2026-06-30 ÷ $39.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 5 of its filings are not read yet.